publication . 2021

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

E. L. Nasonov; A. M. Lila; Vadim I. Mazurov; B. S. Belov; A. E. Karateev; Tatiana Dubinina; O. A. Nikitinskaya; A. A. Baranov; Diana Abdulganieva; S. V. Moiseev; ...
Open Access
  • Published: 15 Jul 2021 Journal: Rheumatology Science and Practice, volume 59, pages 239-254 (issn: 1995-4484, eissn: 1995-4492, Copyright policy)
  • Publisher: Mediar Press
In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.
Persistent Identifiers
Sustainable Development Goals (SDG) [Beta]
free text keywords: Immunology, Immunology and Allergy, Rheumatology, Vaccination, Medicine, business.industry, business, Immune system, Coronavirus disease 2019 (COVID-19), Elderly age, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Intensive care medicine, medicine.medical_specialty, Coronavirus, medicine.disease_cause, Pandemic, Disease
Related Organizations
Communities with gateway
OpenAIRE Connect image
Any information missing or wrong?Report an Issue